October/November #183 : New Booster in Town: Cobicistat - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


The Show Must Go On

A Capital Affair

From the Editor

Trench Warfare


Letters- October/November 2012


Full-Court Press

What You Need to Know

Jamar Rogers's Voice Will Go On

Olympic Winner Tells the World He's Positive

Pesky Email Spam Offers Clues for Eradicating HIV

Infant Circumcision Grows to Global Debate

Why Folks With HIV Can Be Excellent Transplant Recipients

We Hear You

Dr. No

POZ Survey Says

Taking Risks to Help Others

What Matters to You

Finding an HIV Vaccine

Treatment News

Detecting the Missing Link Between HIV and Brain Drain

Point of Reentry: Getting Prisoners HIV Care

New Booster in Town: Cobicistat

Bronx Cheer: An HIV Testing Program Shows Progress

The "War on Drugs" Spreads HIV

Comfort Zone

Dear Diary

POZ Heroes

Hip-Hop Soul

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

October / November 2012

New Booster in Town: Cobicistat

by Laura Whitehorn

Cobicistat, a new pharmacokinetic (PK) enhancer from Gilead Sciences, is set to unseat Abbott’s Norvir (ritonavir) as the only approved HIV treatment booster. It’s key in the newly approved Stribild tablet (a.k.a. the Quad). It will also be sold as a stand-alone drug for use with other HIV meds, along with plans to combine it in tablets with Prezista (darunavir) and Reyataz (atazanavir).

PK enhancers slow the rate at which certain HIV drugs are metabolized in the liver by enzymes. This helps boost the blood levels of the medications, making them easier to take and more effective against the virus.

Many protease inhibitors require boosting. So does elvitegravir, the integrase inhibitor in Stribild, which also contains tenofovir and emtricitabine.
Compared with Norvir, cobicistat has no activity against HIV and doesn’t block as many liver enzymes, meaning that it won’t likely have as many drug interactions.  It does, however, have many of the same side effects as Norvir. 

Search: Cobicistat, pharmacokinetic enhancer, Gilead Sciences, Norvir, Stribild, liver enzymes

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.